Rani Therapeutics Holdings, Inc. Class A Common Stock RANI
HEALTHCARE · BIOTECHNOLOGYi
Market datapartial · fetched 2026-11-04T07:04:14.842Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2027-01-15
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-04T00:28:48.537940624Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-04T07:04:13.074597+00:00
Rani Therapeutics Holdings, Inc. Class A Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 0.58 | 471.3% | 66.6% | |||
| 25Δ | 0.62 | 438.9% | 60.6% | |||
| 30Δ | 0.67 | 406.4% | 54.6% | |||
| 35Δ | 0.71 | 374.0% | 48.6% | |||
| 40Δ | 0.75 | 341.5% | 42.6% | |||
| 45Δ | 0.80 | 309.0% | 36.6% | |||
| 50Δ | 0.84 | 276.6% | 30.5% | |||
| 55Δ | 0.89 | 244.1% | 24.5% | |||
| 60Δ | 0.93 | 211.7% | 18.5% | |||
| 65Δ | 0.97 | 179.2% | 12.5% | |||
| 70Δ | 1.10 | 162.5% | 8.2% | |||
| 75Δ | 1.34 | 166.8% | 6.0% | |||
| 80Δ | 1.58 | 171.1% | 3.8% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.58
- IV
- 471.3%
- B/E move
- 66.6%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.62
- IV
- 438.9%
- B/E move
- 60.6%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.67
- IV
- 406.4%
- B/E move
- 54.6%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.71
- IV
- 374.0%
- B/E move
- 48.6%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.75
- IV
- 341.5%
- B/E move
- 42.6%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.80
- IV
- 309.0%
- B/E move
- 36.6%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.84
- IV
- 276.6%
- B/E move
- 30.5%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.89
- IV
- 244.1%
- B/E move
- 24.5%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.93
- IV
- 211.7%
- B/E move
- 18.5%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.97
- IV
- 179.2%
- B/E move
- 12.5%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.10
- IV
- 162.5%
- B/E move
- 8.2%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.34
- IV
- 166.8%
- B/E move
- 6.0%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.58
- IV
- 171.1%
- B/E move
- 3.8%
Options history
No recorded observations
Biotechnology
RAPP
Rapport Therapeutics, Inc. is a pioneering biotechnology company dedicated to the advancement of therapeutics for neurodegenerative diseases, especially Alzheimer's and associated…
More →RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of…
More →RCKT
Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases. The company is…
More →RCUS
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States. The company is headquartered in Hayward,…
More →REGN
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their…
More →REPL
Replimune Group, Inc., a biotechnology company, develops oncolytic immunogenic therapies to treat cancer. The company is headquartered in Woburn, Massachusetts.
More →